To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 156 participants.

Also called NCT04659070

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 156 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04659070
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04659070. Randomized; triple masking; primary purpose treatment. Start 2020-07-15 (actual); primary completion 2022-05-19 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
Condition
Primary Hypercholesterolemia
Condition
Hypertension
Intervention (Drug)
Experimental : Ezetimibe / Rosuvastatin + Telmisartan
Intervention (Drug)
Active comparator1 : Ezetimibe / Rosuvastatin
Intervention (Drug)
Active comparator2 : Telmisartan
Lead sponsor
Hanlim Pharm. Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04659070
Content hash
cd1b09f8158353b3f74ce294ca1cab0c37017c0c0d1cc893b0c42c0d17fa8c16